Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexmedetomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.50 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medetomidine SCHEMBL18497244 | 1.00 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL29431568 | 1.00 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL12092460 | 1.00 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL26432 | 1.00 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL787913 | 1.00 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL14861666 | 1.00 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL14080529 | 0.98 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL22616139 | 0.98 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL22476079 | 0.98 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL204843 | 0.98 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9845 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144787-A1 | COMPOSITIONS AND METHODS FOR TREATING STIMULANT-INDUCED AGITATION | MARSHALL UNIVERSITY RESEARCH CORPORATION (US) | 2026-05-28 | — | — | US | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137633-A1 | DEXMEDETOMIDINE MICRONEEDLE PATCH, PREPARATION METHOD AND APPLICATION THEREOF | GUANGZHOU NOVAKEN PHARM CO LTD (CN) | 2026-05-21 | — | — | US | claimed |
| US-12629354-B2 | Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof | TAIWAN LIPOSOME CO., LTD. (TW) | 2026-05-19 | — | — | US | claimed |
| US-20260132115-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TIANJIN GUDUI BIO PHARM CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4739298-A1 | ACTIVATORS OF THE XC- SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731214-A1 | DEXMEDETOMIDINE TREATMENT REGIMENS | BioXcel Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12599332-B2 | Non-invasive assessment of glymphatic flow and neurodegeneration from a wearable device | Applied Cognition, Inc. (US) | 2026-04-14 | — | — | US | claimed |
| WO-1993025199-A1 | ALPHA-2-ADRENERGIC AGONISTS FOR TREATING PRESBYOPIA | TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) | 1993-12-23 | — | — | WO | claimed |
| US-5217718-A | Using pressure sensitive adhesive skin patch | CYGNUS THERAPEUTIC SYSTEMS (US) | 1993-06-08 | — | — | US | claimed |
| WO-1993007842-A1 | THERMAL ENHANCEMENT OF TRANSDERMAL DRUG ADMINISTRATION | CYGNUS THERAPEUTIC SYSTEMS (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0424059-B1 | USE OF SUSTITUTED IMIDAZOLES FOR THE MANUFACTURE OF AN ANALGESIC | ORION-YHTYMÀ OY (FI) | 1993-03-03 | — | — | EP | claimed |
| US-5124157-A | Using adhesive skin patch | CYGNUS THERAPEUTIC SYSTEMS (US) | 1992-06-23 | — | — | US | claimed |
| US-5091402-A | Local epidural or intraspinal administration for analgesia without sedation | ORION-YHTYMA OY (FI) | 1992-02-25 | — | — | US | claimed |
| EP-0424059-A1 | Use of sustituted imidazoles for the manufacture of an analgesic | ORION-YHTYMÀ OY (FI) | 1991-04-24 | — | — | EP | claimed |
| WO-1991002505-A1 | METHOD AND DEVICE FOR ADMINISTERING DEXMEDETOMIDINE TRANSDERMALLY | CYGNUS RESEARCH CORPORATION (US) | 1991-03-07 | — | — | WO | claimed |
| CN-1049450-A | Method and apparatus that dexmedetomidine uses through skin | CYGNUS RESEARCH CORP (US) | 1991-02-27 | — | — | CN | claimed |
| EP-0413487-A1 | Method and device for administering dexmedetomidine transdermally | CYGNUS THERAPEUTIC SYSTEMS (US) | 1991-02-20 | — | — | EP | claimed |